Search clinical trials for: Octreotide DG3173 Placebo

Total 53996 results

Aspireo Pharmaceuticals Limited

Completed

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

Healthy
Aspireo Pharmaceuticals Limited

Completed

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

Acromegaly
Aspireo Pharmaceuticals Limited

Completed

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Acromegaly
Aspireo Pharmaceuticals Limited

Completed

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Healthy
Aspireo Pharmaceuticals Limited
DeveloGen AG, Germany

Completed

Single Ascending Dose Tolerability Study of DG3173

Healthy
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
Chiasma, Inc.

Unknown

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (OPTIMAL)

Acromegaly

United States, Israel, Canada, Denmark, Netherlands, New Zealand, Australia, United Kingdom, Hungary, Italy, Poland, Bulgaria, Germany, Latvia, Slovenia, Sweden, Turkey
Camurus AB

Completed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (ACROINNOVA 1)

Acromegaly

United States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
St. Josef Hospital Bochum

Completed

Effects of Intraarterial Octreotide on Pancreatic Texture

Pancreatic Fistula

Germany
Mayo Clinic
Novartis; National Center for Research Resources (NCRR)

Completed

Octreotide in Severe Polycystic Liver Disease

Liver Diseases | Abdominal Pain | Polycystic Kidney, Autosomal Dominant | Hepatomegaly | Polycystic Liver Disease | Kidney, Polycystic

United States
University College, London
National Institute for Health Research, United Kingdom

Active, not recruiting

A Feasibility Study of Octreotide Infusion During Liver Transplant. (Octreotide)

Liver Transplantation | Renal Failure

United Kingdom
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Colorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation Enteritis

United States
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Hadassah Medical Organization

Unknown

Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery

Fistula; Salivary Duct or Gland

Israel
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Sarcoma | Cervical Cancer | Diarrhea | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer
Novartis

Completed

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

Irritable Bowel Syndrome (IBS)

United Kingdom, United States, Canada, Sweden
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Acromegaly

Germany
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Carmen Schade-Brittinger

Completed

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Neuroendocrine Tumors

Germany
Camurus AB

Active, not recruiting

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (POSITANO)

Polycystic Liver Disease

United States, Germany, Belgium, Netherlands
AdventHealth

Terminated

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Adenoma

United States
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Mayo Clinic

Completed

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Cirrhosis | Portal Hypertension | Esophageal Varices
Chengfeng Wang

Unknown

The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial

Pancreatic Diseases

China
Novartis Pharmaceuticals

Completed

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea (LARCID)

Chemotherapy-induced Diarrhea

Brazil
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

Healthy Volunteers

China
Peking University

Unknown

Octreotide LAR as Maintenance Treatment for Patients With NEC

Esophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic Carcinoma

China
Federico II University

Completed

Effects of Somatostatin on ADPKD Heart

Autosomal Dominant Polycystic Kidney Disease | Glomerular Filtration Rate > 40 ml/Min
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Federico II University

Completed

Effects of Somatostatin on Liver in ADPKD

Autosomal Dominant Polycystic Kidney Disease
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Lymphorrhea

Italy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Acromegaly

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (SCIROCCO)

Neuroendocrine Tumors | Carcinoid Syndrome
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Novartis

Completed

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Prostate Cancer

Italy
Institut National de la Santé Et de la Recherche...

Completed

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide (FIBROSAND)

Idiopathic Pulmonary Fibrosis
National Center for Research Resources (NCRR)
Yale University

Completed

Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia

Hereditary Hemorrhagic Telangiectasia | Ectasia
Duke University

Completed

Effect of Octreotide on Saliva

Healthy

United States
University Hospital, Rouen

Completed

Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone (SAPORO)

Acromegaly

France
Mario Negri Institute for Pharmacological Research

Recruiting

Outcome of ADPKD With Octreotide LAR (ADPKD648)

Autosomal Dominant Polycystic Kidney

Italy
Fredrik Klevebro
Karolinska University Hospital

Recruiting

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer (OTIS)

Gastric Cancer | Esophageal Cancer

Sweden
Novartis Pharmaceuticals

Completed

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

Healthy Cholecystectomized

France, Italy, Belgium
Novartis

Completed

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Acromegaly
Federico II University

Completed

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly (HDacro)

Acromegaly

Italy
Novartis Pharmaceuticals

Terminated

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Acromegaly

Mexico

Search clinical trials for: Octreotide DG3173 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations